MenAfriVac

Outlook on the Meningococcal Vaccines Global Market to 2030 - Increasing Immunization Programs and Government Initiatives is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 14, 2022
Infectious Diseases, Pharmaceutical, Health, Inactivated vaccine, Sanofi, Goal, NIP, ECDC, Meningitis Vaccine Project, Disease, Government, National Center for Immunization and Respiratory Diseases, Organization, WHO, Meningitis, MenAfriVac, Vaccine, FDA, Growth, Profile, Meningococcal disease, Incidence, Prevalence, Epidemic, CAGR, USD, Pharmaceutical industry, Meningococcal vaccine, Meningococcal vaccine, Serotype, EU, Meningococcal vaccine

The global meningococcal vaccines market size is expected to reach USD 4.92 billion by 2030, registering a CAGR of 6.2%.

Key Points: 
  • The global meningococcal vaccines market size is expected to reach USD 4.92 billion by 2030, registering a CAGR of 6.2%.
  • In addition, rising FDA approval for meningococcal vaccines is expected to boost the growth.
  • The increase in approval of novel vaccines is expected to improve meningococcal prevention which in turn, is anticipated to drive the market.
  • Initiatives undertaken by the government to combat the rising incidence of the disease are anticipated to boost the meningococcal vaccine market growth.

Meningitis Canada Calls on Governments to Fund Meningitis B Vaccine

Retrieved on: 
Monday, June 28, 2021
Vaccination, Medical specialties, Clinical medicine, Medicine, Meningitis, Immunization, Vaccine, MenAfriVac

WATERLOO, Ontario, June 28, 2021 (GLOBE NEWSWIRE) -- In the wake of the tragic death of 19-year-old Kai Matthews of Halifax, Nova Scotia, Meningitis Foundation Canada (MFC) calls on all Canadian provinces and territories to include meningitis B on their routine immunization schedules.

Key Points: 
  • WATERLOO, Ontario, June 28, 2021 (GLOBE NEWSWIRE) -- In the wake of the tragic death of 19-year-old Kai Matthews of Halifax, Nova Scotia, Meningitis Foundation Canada (MFC) calls on all Canadian provinces and territories to include meningitis B on their routine immunization schedules.
  • Despite being approved, many young Canadians and their families are not aware of the meningitis B vaccines and therefore have not been immunized.
  • If the COVID-19 pandemic has taught us anything, it has driven home the cold hard fact that vaccine prevention saves lives.
  • For more information on meningitis and how to protect against this deadly disease, visit www.meningitis.ca or Join Us on Facebook , Twitter and Instagram .

Insights on the Meningococcal Vaccine Global Market to 2026 - Featuring GlaxoSmithKline, Pfizer and Sanofi Among Others

Retrieved on: 
Tuesday, April 20, 2021
Medical specialties, Bacteria, Clinical medicine, Bacterial diseases, Vaccine-preventable diseases, Meningitis, Meningococcal disease, Sepsis, Neisseria meningitidis, MenAfriVac, Viral meningitis

In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics.

Key Points: 
  • In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics.
  • According to the Centers for Disease Control and Prevention (CDC), about 1.2 million cases of meningococcal meningitis are estimated to occur worldwide every year.
  • The government and regulatory authorities are taking initiatives to combat the increasing prevalence of meningitis are likely to drive the market growth.
  • North America led the market and had a significant revenue share of the market in 2019 which is followed by Europe.

Meningococcal Vaccine Market to Reach $4.19 Bn, Globally, by 2026 at 9.5% CAGR: AMR

Retrieved on: 
Tuesday, May 19, 2020
Medical specialties, Medicine, Infectious diseases, RTT, Vaccines, Vaccine-preventable diseases, Vaccination, Meningococcal disease, Meningococcal vaccine, Vaccine, MenAfriVac, NmVac4-A/C/Y/W-135

According tothe report, the global meningococcal vaccine industry generated $1.93 billion in 2018, and is estimated to reach $4.19 billion by 2026, growing at a CAGR of 9.5% from 2019 to 2026.

Key Points: 
  • According tothe report, the global meningococcal vaccine industry generated $1.93 billion in 2018, and is estimated to reach $4.19 billion by 2026, growing at a CAGR of 9.5% from 2019 to 2026.
  • Rise in outbreaks of meningococcal disease, increase in immunization programs across the world, and surge in research and development for vaccine technology drive the global meningococcal vaccine market.
  • However, long duration required for vaccine production and high cost of vaccine development hinder the market growth.
  • Based on vaccine type, the conjugate segment held the largest share of the global meningococcal vaccine market, accounting for nearly half of the total market share in 2018, and is estimated to maintain its lead by 2026.

Meningococcal Vaccine Market to Reach $4.19 Bn, Globally, by 2026 at 9.5% CAGR: AMR

Retrieved on: 
Tuesday, May 19, 2020
Medical specialties, Medicine, Vaccination, Vaccines, RTT, Vaccine-preventable diseases, Meningococcal disease, Meningococcal vaccine, Vaccine, MenAfriVac, NmVac4-A/C/Y/W-135

According tothe report, the global meningococcal vaccine industry generated $1.93 billion in 2018, and is estimated to reach $4.19 billion by 2026, growing at a CAGR of 9.5% from 2019 to 2026.

Key Points: 
  • According tothe report, the global meningococcal vaccine industry generated $1.93 billion in 2018, and is estimated to reach $4.19 billion by 2026, growing at a CAGR of 9.5% from 2019 to 2026.
  • Rise in outbreaks of meningococcal disease, increase in immunization programs across the world, and surge in research and development for vaccine technology drive the global meningococcal vaccine market.
  • However, long duration required for vaccine production and high cost of vaccine development hinder the market growth.
  • Meningococcal vaccine is used as a placebo effect in the Covid-19 vaccine trial conducted at the University of Oxford.

National Meningitis Association Urges Parents to Get Their Teens The 16 Vaccine to Help Protect Against Meningococcal Meningitis

Retrieved on: 
Monday, September 17, 2018
Bacteria, Medicine, Microbiology, Vaccination, Meningococcal disease, Sepsis, Neisseria meningitidis, Meningitis, Vaccine, MenAfriVac

The 16 Vaccine ( The16Vaccine.org ) aims to educate parents about the importance of this critical second dose of MenACWY, which helps protect teens against meningococcal meningitis during the period when they are at increased risk.

Key Points: 
  • The 16 Vaccine ( The16Vaccine.org ) aims to educate parents about the importance of this critical second dose of MenACWY, which helps protect teens against meningococcal meningitis during the period when they are at increased risk.
  • "Some parents are aware of the primary dose of MenACWY vaccine at 11-12 years of age, but they don't know CDC recommends a second dose at age 16.
  • The campaign website features emotional firsthand stories of meningococcal meningitis survivors and advocates whose lives have been irrevocably impacted by the disease.
  • Parents can also sign up for a text reminder at The16Vaccine.org, which will alert parents when it's time to schedule an appointment for their teen's 16-year vaccine visit.